Rosuvastatin in Diabetic Hemodialysis Patients
Journal of the American Society of Nephrology, 05/16/2011

Holdaas H et al. – Among hemodialysis patients with diabetes mellitus, rosuvastatin might reduce the risk of fatal and nonfatal cardiac events.

• Post hoc analysis
• 731 participants with diabetes
• Traditional risk factors such as LDL–C, smoking, and BP did not associate with cardiac events (cardiac death and nonfatal myocardial infarction).
• At baseline, only age and high–sensitivity C–reactive protein were independent risk factors for cardiac events.

• Assignment to rosuvastatin associated with a nonsignificant 16.2% reduction in risk for the AURORA trial's composite primary endpoint of cardiac death, nonfatal MI, or fatal or nonfatal stroke (HR 0.84; 95% CI 0.65 to 1.07).
• There was no difference in overall stroke
• Rosuvastatin group had more hemorrhagic strokes than the placebo group (12 versus two strokes, respectively; HR, 5.21; 95% CI 1.17 to 23.27)
• Rosuvastatin treatment significantly reduced the rates of cardiac events by 32% among patients with diabetes (HR 0.68; 95% CI 0.51 to 0.90).